Genovate Biotechnology Co (ROCO:4130) Altman Z2-Score: 14.25 (As of Jul. 14, 2026) — 12% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4130 Genovate Biotechnology Co Ltd ROCO:4130
72 GF Score
Price NT$26.85
GF Value NT$22.20
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Genovate Biotechnology Co Altman Z2-Score?

Genovate Biotechnology Co ROCO:4130 -4.62% 72 Altman Z2-Score is 14.25 as of Jul. 14, 2026, which is 12% above its 10-year median of 12.75. GuruFocus rates ROCO:4130 with a GF Score™ of 72/100 and a GF Value™ of NT$22.20 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 1,392 Biotechnology companies, Genovate Biotechnology Co ranks better than 88.51% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Good Sign:

Genovate Biotechnology Co has a Altman Z2-Score of 14.25, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Genovate Biotechnology Co's Altman Z2-Score or its related term are showing as below:

ROCO:4130' s Altman Z2-Score Range Over the Past 10 Years
Min: 6.56   Med: 12.75   Max: 14.55
Current: 14.25

During the past 13 years, Genovate Biotechnology Co's highest Altman Z2-Score was 14.55. The lowest was 6.56. And the median was 12.75.


Genovate Biotechnology Co  (ROCO:4130) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Genovate Biotechnology Co Altman Z2-Score Related Terms


Genovate Biotechnology Co Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for Genovate Biotechnology Co's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genovate Biotechnology Co Altman Z2-Score Chart

Genovate Biotechnology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.12 12.55 14.55 13.66 14.25

Genovate Biotechnology Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.66 12.03 13.41 14.47 14.25

ROCO:4130 vs VRTX, REGN, ALNY: Altman Z2-Score Comparison

For the Biotechnology subindustry, Genovate Biotechnology Co's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genovate Biotechnology Co Altman Z2-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genovate Biotechnology Co's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Genovate Biotechnology Co's Altman Z2-Score falls into.


ROCO:4130
72GF Score
Genovate Biotechnology Co Ltd ROCO:4130
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genovate Biotechnology Co Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Genovate Biotechnology Co's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.3943+3.26*0.0303+6.72*0.0094+1.05*10.9507
=14.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2025:
Total Assets was NT$1,506.4 Mil.
Total Current Assets was NT$719.3 Mil.
Total Current Liabilities was NT$125.3 Mil.
Retained Earnings was NT$45.7 Mil.
Pre-Tax Income was -5.711 + -1.767 + 8.628 + 12.304 = NT$13.5 Mil.
Interest Expense was -0.146 + -0.165 + -0.182 + -0.19 = NT$-0.7 Mil.
Total Liabilities was NT$126.0 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(719.298 - 125.322)/1506.369
=0.3943

X2=Retained Earnings/Total Assets
=45.68/1506.369
=0.0303

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(13.454 - -0.683)/1506.369
=0.0094

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(1380.32 - 0)/126.049
=10.9507

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Genovate Biotechnology Co has a Altman Z2-Score of 14.25 indicating it is in Safe Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of 14.25 mean?
Genovate Biotechnology Co (ROCO:4130) has a Altman Z2-Score of 14.25 as of Jul. 14, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Genovate Biotechnology Co and its competitors. This is 12% above median its historical median of 12.75. Over the past decade, Genovate Biotechnology Co's Altman Z2-Score has ranged from 6.56 to 14.55. According to the industry distribution chart, Genovate Biotechnology Co ranks #160 out of 1392 companies in the Biotechnology industry, placing it in the top 11.5%.
Is Genovate Biotechnology Co's Altman Z2-Score too high?
Genovate Biotechnology Co's current Altman Z2-Score of 14.25 is 12% above median its 10-year median of 12.75. Over the past 10 years, this metric has ranged from a low of 6.56 to a high of 14.55. Based on the distribution chart, Genovate Biotechnology Co ranks #160 out of 1392 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genovate Biotechnology Co has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genovate Biotechnology Co's Altman Z2-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genovate Biotechnology Co ranks #160 out of 1392 companies for Altman Z2-Score. This places Genovate Biotechnology Co in the top 12% of its industry — outperforming the majority of peers. Historically, Genovate Biotechnology Co's own Altman Z2-Score has ranged from 6.56 to 14.55 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Biotechnology company?
A good Altman Z2-Score depends on the Biotechnology industry context. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Genovate Biotechnology Co and its competitors. Genovate Biotechnology Co's current Altman Z2-Score is 14.25, which is 12% above median its own 10-year median of 12.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genovate Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Genovate Biotechnology Co (ROCO:4130) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$22.20, compared to a current price of NT$26.85 — trading 20.9% above its estimated fair value. The current Altman Z2-Score is 14.25, which is 12% above median its 10-year median of 12.75. Genovate Biotechnology Co's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Genovate Biotechnology Co (ROCO:4130), the current Altman Z2-Score is 14.25 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genovate Biotechnology Co (ROCO:4130) Overvalued in 2026?

Based on GuruFocus' analysis, Genovate Biotechnology Co stock appears to be overvalued. The current stock price of NT$26.85 is trading 20.9% above its estimated GF Value™ of NT$22.20. GuruFocus considers Genovate Biotechnology Co to be Modestly Overvalued.

Key valuation signals for ROCO:4130:

  • Altman Z2-Score: 14.25 (12% above median its 10-year median of 12.75)
  • GF Value™: NT$22.20 vs. price of NT$26.85 (20.9% above fair value)
  • GF Score™: 72/100 with 3 warning signs

No single metric tells the full story. See the ROCO:4130 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genovate Biotechnology Co Business Description

Address No.1, First Industrial Road, Hsin-Chu Expanded Park, Hukou Township, Guangdong Province, Hsin-Chu county, Hsin-Chu, TWN, 303036
Genovate Biotechnology Co Ltd develops, produces, manufactures, and sales of medicines for the prevention and treatment of diseases caused by viruses and bacteria, and medicines for the treatment of cardiovascular, gastrointestinal, cancer, and autoimmune diseases, etc. The company is also engaged in the sales of medicines for the prevention and treatment of diseases caused by viruses and bacteria, and medicines for the treatment of cardiovascular, gastrointestinal, cancer, and autoimmune diseases etc.
72GF Score

Get the complete analysis for ROCO:4130

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$26.85
Price
NT$22.20
GF Value